Literature DB >> 21775172

Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study.

Raphaële Renard-Penna1, Morgan Rouprêt, Eva Comperat, Amine Ayed, Mathieu Coudert, Pierre Mozer, Evanguelos Xylinas, Marc-Olivier Bitker, Philippe Grenier.   

Abstract

OBJECTIVE: To evaluate the role of pelvic phased array MRI in staging prostate cancer (CaP).
MATERIALS AND METHODS: We prospectively collected data over 12 months on CaP patients who underwent preoperative MR imaging with a pelvic phased array before radical prostatectomy. MR images were analyzed prospectively by 2 radiologists. MR imaging findings were then correlated with pathologic findings.
RESULTS: Overall, 101 patients were included with a mean PSA level of 8 (range 1.8-30). Reader 1 (AUC 0.895, 95% CI 0.791-0.999) had a higher performance than reader 2 (AUC 0.687, 95% CI, 0.555-0.819) and than DRE (AUC 0.728, 95% CI, 0.599-0.857) in discriminating T2 from T3 CaP (P = 0.01). The κ-index of inter-observer agreement was 0.56. A model that combines MRI findings, DRE, PSA, and Gleason score was the most competitive for staging (AUC 0.895, 95% CI, 0.791-0.999). For the multivariate analysis, 3 criteria were significantly associated with extracapsular extension: asymmetry of the neuro-vascular bundles (P = 0.001), asymmetric enhancement of neurovascular bundles (P = 0.02), and bulging of the capsule (P = 0.0003).
CONCLUSION: Pelvic phased array MRI presented satisfying results in its ability to adequately stage CaP and notably in detecting the extracapsular extension of tumors. It is likely to provide reliable information but rather in the hands of an experienced radiologist.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775172     DOI: 10.1016/j.urolonc.2011.02.017

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  14 in total

Review 1.  Image-guided robotic interventions for prostate cancer.

Authors:  Ashwin N Sridhar; Archie Hughes-Hallett; Erik K Mayer; Philip J Pratt; Philip J Edwards; Guang-Zhong Yang; Ara W Darzi; Justin A Vale
Journal:  Nat Rev Urol       Date:  2013-06-18       Impact factor: 14.432

2.  Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.

Authors:  Raphaele Renard Penna; Geraldine Cancel-Tassin; Eva Comperat; Pierre Mozer; Priscilla Léon; Justine Varinot; Morgan Roupret; Marc-Olivier Bitker; Olivier Lucidarme; Olivier Cussenot
Journal:  World J Urol       Date:  2016-02-22       Impact factor: 4.226

Review 3.  The role for surgery in high-risk prostate cancer.

Authors:  Cécilia Lanchon; Shahrokh F Shariat; Morgan Rouprêt
Journal:  Wien Med Wochenschr       Date:  2015-09-23

4.  Oncologic outcomes after minimally invasive radical prostatectomy in patients with seminal vesicle invasion (pT3b) without adjuvant therapy.

Authors:  Aurélien Forgues; François Rozet; François Audenet; Adil Ouzzane; Rafaël Sanchez-Salas; Eric Barret; Marc Galiano; Dominique Prapotnich; Xavier Cathelineau
Journal:  World J Urol       Date:  2013-07-24       Impact factor: 4.226

5.  Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination.

Authors:  Evanguelos Xylinas; David R Yates; Raphaële Renard-Penna; Elise Seringe; Jean-Claude Bousquet; Eva Comperat; Marc-Olivier Bitker; Philippe Grenier; Morgan Rouprêt
Journal:  World J Urol       Date:  2011-12-23       Impact factor: 4.226

6.  Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study.

Authors:  Raphaële Renard-Penna; Morgan Roupret; Eva Compérat; François Rozet; Benjamin Granger; Johann Barkatz; Marc Olivier Bitker; Olivier Lucidarme; Olivier Cussenot; Pierre Mozer
Journal:  World J Urol       Date:  2015-09-24       Impact factor: 4.226

7.  Multiparametric magnetic resonance imaging for prostate cancer-a comparative study including radical prostatectomy specimens.

Authors:  Liam Toner; Nathan Papa; Marlon Perera; Nikolas Katelaris; Mahesha Weerakoon; Kwang Chin; Laurence Harewood; Damien M Bolton; Nathan Lawrentschuk
Journal:  World J Urol       Date:  2016-10-26       Impact factor: 4.226

8.  Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline.

Authors:  Jennifer Salerno; Antonio Finelli; Chris Morash; Scott C Morgan; Nicholas Power; Nichola Schieda; Masoom A Haider
Journal:  Can Urol Assoc J       Date:  2016-10-13       Impact factor: 1.862

9.  Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology.

Authors:  Lars Boesen; Elizaveta Chabanova; Vibeke Løgager; Ingegerd Balslev; Kari Mikines; Henrik S Thomsen
Journal:  Eur Radiol       Date:  2014-12-11       Impact factor: 5.315

10.  Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?

Authors:  Raïssa Lotte; Alexandre Lafourcade; Pierre Mozer; Pierre Conort; Eric Barret; Eva Comperat; Malek Ezziane; Paul-Hugo Jouve de Guibert; Sebastian Tavolaro; Lisa Belin; Franck Boudghene; Olivier Lucidarme; Raphaële Renard-Penna
Journal:  Eur Radiol       Date:  2018-04-09       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.